Literature DB >> 10715264

Troglitazone improves recovery of left ventricular function after regional ischemia in pigs.

P Zhu1, L Lu, Y Xu, G G Schwartz.   

Abstract

BACKGROUND: This study determined whether treatment of normal (nondiabetic) pigs with the insulin-sensitizing agent troglitazone improves recovery of left ventricular (LV) function after acute ischemia and whether such effects are associated with altered myocardial substrate metabolism. METHODS AND
RESULTS: Juvenile pigs (n=6) were treated with troglitazone (75 mg. kg(-1). d(-1) PO) for 8 weeks. Untreated pigs (n=8) served as controls. Under anesthetized, open-chest conditions, pigs underwent 90 minutes of moderate regional LV ischemia and 90 minutes of reperfusion. Regional LV function was assessed with subendocardial sonomicrometry crystals. Fasting plasma insulin and free fatty acid levels were lower in troglitazone-treated pigs than in untreated pigs, whereas blood glucose did not differ between groups. These findings suggest that treatment enhanced systemic insulin sensitivity. Baseline hemodynamics and regional LV function did not differ between groups. After ischemia and reperfusion, systolic function (external work) of the ischemic region recovered to 44+/-6% of baseline in troglitazone-treated pigs versus 18+/-6% of baseline in untreated pigs (P<0.05). Regional diastolic function (maximum rate of wall expansion) recovered to 78+/-7% of baseline in treated pigs versus 52+/-7% of baseline in untreated pigs (P<0.05). Recovery of global LV systolic and diastolic function was also significantly greater in treated pigs. Myocardial glucose uptake did not differ between groups under any condition; however, net myocardial lactate uptake after reperfusion was 7 times greater in troglitazone-treated pigs than in untreated pigs, suggesting that treatment enhanced myocardial carbohydrate oxidation after reperfusion.
CONCLUSIONS: In nondiabetic pigs, chronic troglitazone treatment improves recovery of LV systolic and diastolic function after acute ischemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715264      PMCID: PMC3633448          DOI: 10.1161/01.cir.101.10.1165

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Authors:  M N Ghazzi; J E Perez; T K Antonucci; J H Driscoll; S M Huang; B W Faja; R W Whitcomb
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

Review 2.  Glucose metabolism in the ischemic heart.

Authors:  G D Lopaschuk; W C Stanley
Journal:  Circulation       Date:  1997-01-21       Impact factor: 29.690

3.  Low-dose inotropic stimulation during left ventricular ischaemia does not worsen post-ischaemic dysfunction.

Authors:  G G Schwartz; Y Xu; C Greyson; J Cohen; L Lu
Journal:  Cardiovasc Res       Date:  1996-12       Impact factor: 10.787

4.  Troglitazone has a scavenging effect on reactive oxygen species.

Authors:  I Inoue; S Katayama; K Takahashi; K Negishi; T Miyazaki; M Sonoda; T Komoda
Journal:  Biochem Biophys Res Commun       Date:  1997-06-09       Impact factor: 3.575

5.  Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig.

Authors:  Y Nakamura; Y Ohya; U Onaka; K Fujii; I Abe; M Fujishima
Journal:  Br J Pharmacol       Date:  1998-02       Impact factor: 8.739

6.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

Authors:  S Schwartz; P Raskin; V Fonseca; J F Graveline
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

7.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Authors:  S E Inzucchi; D G Maggs; G R Spollett; S L Page; F S Rife; V Walton; G I Shulman
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.

Authors:  M Shimoyama; K Ogino; Y Tanaka; T Ikeda; I Hisatome
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

Review 9.  Troglitazone in type II diabetes mellitus.

Authors:  N Sparano; T L Seaton
Journal:  Pharmacotherapy       Date:  1998 May-Jun       Impact factor: 4.705

Review 10.  Thiazolidinediones--tools for the research of metabolic syndrome X.

Authors:  R Komers; A Vrána
Journal:  Physiol Res       Date:  1998       Impact factor: 1.881

View more
  19 in total

1.  Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs.

Authors:  P Zhu; L Lu; Y Xu; C Greyson; G G Schwartz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-02       Impact factor: 4.733

Review 2.  Minireview: Challenges and opportunities in development of PPAR agonists.

Authors:  Matthew B Wright; Michele Bortolini; Moh Tadayyon; Martin Bopst
Journal:  Mol Endocrinol       Date:  2014-08-22

3.  Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Michael O'Connor; Basilia Zingarelli
Journal:  Int J Clin Exp Med       Date:  2010-01-01

Review 4.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Authors:  Janice V Huang; Clifford R Greyson; Gregory G Schwartz
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

5.  Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.

Authors:  Yang Yu; Zhi-Hua Zhang; Shun-Guang Wei; Robert M Weiss; Robert B Felder
Journal:  Hypertension       Date:  2011-11-14       Impact factor: 10.190

6.  PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.

Authors:  Ya Xu; Michael Gen; Li Lu; Jennifer Fox; Sara O Weiss; R Dale Brown; Daniel Perlov; Hasan Ahmad; Peili Zhu; Clifford Greyson; Carlin S Long; Gregory G Schwartz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-11-04       Impact factor: 4.733

7.  Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Alvin Denenberg; Basilia Zingarelli
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

Review 8.  Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

Authors:  C E Quinn; P K Hamilton; C J Lockhart; G E McVeigh
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

Review 9.  Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy.

Authors:  N Fillmore; J Mori; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

10.  Conditional deletion of cardiomyocyte peroxisome proliferator-activated receptor γ enhances myocardial ischemia-reperfusion injury in mice.

Authors:  Michael J Hobson; Paul W Hake; Michael O'Connor; Christine Schulte; Victoria Moore; Jeanne M James; Giovanna Piraino; Basilia Zingarelli
Journal:  Shock       Date:  2014-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.